Child Pneumococcal Serotype Epidemiology In Greece

Pfizer

Status: Completed

Conditions: Pneumococcal Disease

Treatments: Other: no intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT01111214

B1841010

0887X1-4434

Details and patient eligibility

About

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program.

The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

Full description

open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD

Enrollment: 457 patients

Sex: All

Ages: Under 14 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children aged 14 years old or less.
• Hospitalized in a participating healthcare facility with an IPD.
• IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion criteria

• Children > 14 years of age
• Unconfirmed IPD

Trial design

457 participants in 1 patient group

group 1

Description:

Hospitalized children ≤14 years of age with invasive pneumococcal disease

Treatment:

Other: no intervention